Two Sigma Investments’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-27,800
| Closed | -$44.2K | – | 3459 |
|
|
2024
Q1 | $44.2K | Sell |
27,800
-462,716
| -94% | -$686K | ﹤0.01% | 2889 |
|
|
2023
Q4 | $421K | Buy |
490,516
+83,688
| +21% | +$73.5K | ﹤0.01% | 2546 |
|
|
2023
Q3 | $435K | Buy |
406,828
+70,394
| +21% | +$146K | ﹤0.01% | 2337 |
|
|
2023
Q2 | $871K | Sell |
336,434
-5,588
| -2% | -$19.9K | ﹤0.01% | 2015 |
|
|
2023
Q1 | $1.4M | Buy |
342,022
+62,832
| +23% | +$290K | ﹤0.01% | 1668 |
|
|
2022
Q4 | $1.4M | Buy |
279,190
+19,250
| +7% | +$121K | ﹤0.01% | 1524 |
|
|
2022
Q3 | $3.4M | Buy |
259,940
+91,020
| +54% | +$1.38M | 0.01% | 916 |
|
|
2022
Q2 | $2.17M | Buy |
168,920
+21,722
| +15% | +$301K | 0.01% | 1155 |
|
|
2022
Q1 | $2.25M | Sell |
147,198
-89,461
| -38% | -$1.4M | 0.01% | 1301 |
|
|
2021
Q4 | $4.19M | Buy |
236,659
+28,339
| +14% | +$544K | 0.01% | 1301 |
|
|
2021
Q3 | $4.38M | Buy |
208,320
+194,420
| +1,399% | +$4.28M | 0.01% | 1336 |
|
|
2021
Q2 | $274K | Sell |
13,900
-54,247
| -80% | -$1.27M | ﹤0.01% | 3579 |
|
|
2021
Q1 | $1.98M | Buy |
+68,147
| New | +$1.91M | 0.01% | 1717 |
|
|
2020
Q4 | – | Sell |
-49,542
| Closed | -$788K | – | 3874 |
|
|
2020
Q3 | $788K | Buy |
49,542
+727
| +1% | +$13.3K | ﹤0.01% | 1917 |
|
|
2020
Q2 | $964K | Buy |
+48,815
| New | +$933K | ﹤0.01% | 1558 |
|
Two Sigma Investments's NGM Position: Q2 2024 in Review
Two Sigma Investments sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 27,800 shares — an estimated $44.2K sold.
Two Sigma Investments first reported a position in NGM in Q2 2020 and held it in 15 quarters. The position peaked at $4.38M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Two Sigma Investments reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Two Sigma Investments sold 27,800 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $44.2K.
- Two Sigma Investments first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 15 quarters.
- Two Sigma Investments's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4.38M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.